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CONGENITAL/PEDIATRIC CARDIOLOGY
CASE REPORT: CLINICAL CASE SERIES

Cardiac Dysfunction and Shock in
Pediatric Patients With COVID-19
Krittika Joshi, MBBS,a Daniel Kaplan, DO,b Adnan Bakar, MD,b John F. Jennings, MD,b Denise A. Hayes, MD,a
Siddharth Mahajan, MBBS,a Nilanjana Misra, MD,a Elizabeth Mitchell, MD,a Todd M. Sweberg, MD,b
Matthew D. Taylor, MD,b,c Christine A. Capone, MD, MPHb,c

ABSTRACT
Coronavirus disease-2019 (COVID-19) has been reported to cause signiﬁcant morbidity in adults, with reportedly a
lesser impact on children. Cardiac dysfunction has only been described in adults thus far. We describe 3 cases
of previously healthy children presenting with shock and COVID-19–related cardiac inﬂammation.
(Level of Difﬁculty: Intermediate.) (J Am Coll Cardiol Case Rep 2020;2:1267–70) © 2020 The Authors. Published
by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

T

he pandemic caused by coronavirus disease-

PATIENT #1

2019 (COVID-19) continues to inﬂict signiﬁcant morbidity and mortality around the

A 13-year-old previously healthy obese male patient

been

presented to the emergency department (ED) with

reported to be mild. Cardiovascular complications of

5 days of fever, headache, and abdominal pain; 2 days

COVID-19 have been reported in adult literature, but

of diarrhea; and 1 day of shortness of breath. On

pediatric data are lacking. With Northwell Institu-

initial presentation, he was afebrile, tachycardic (119

tional Review Board approval, we describe 3 previ-

beats/min), hypotensive (76/35 mm Hg), and tachyp-

ously healthy children admitted to the pediatric

neic (56 breaths/min), with oxygen saturation of 94%

intensive care unit (PICU) for COVID-19–related shock

on room air. On examination, he had mild crackles at

and evidence of cardiac injury.

lung bases, a regular heart rhythm with a gallop, he-

world.

Most

pediatric

infections

have

patomegaly, and delayed capillary reﬁll time of 4 s. A
norepinephrine infusion was started for ﬂuid re-

LEARNING OBJECTIVES
 To recognize that pediatric COVID-19 may
present with evidence of shock and cardiac
dysfunction independent of lung disease.
 To review the different mechanisms of cardiac
injury in pediatric patients with COVID-19.

fractory

hypotension

along

with

supplemental

oxygen therapy via nonrebreather.
Initial laboratory results showed a leukocytosis
with neutrophil predominance and bandemia, as well
as signiﬁcant elevation in inﬂammatory markers that
have been associated with COVID-19 (C-reactive
protein,

procalcitonin,

lactate

dehydrogenase,
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ABBREVIATIONS

triglycerides, ferritin, D-dimer, and ﬁbrin-

lactate level but was noted to have AKI as well as a

AND ACRONYMS

ogen). High-sensitivity troponin T (hsTnT)

mild transaminitis. His hsTnT was elevated to 116 ng/l

was elevated to 389 ng/l (<6 to 14 ng/l). The

(<6 to 14 ng/l). A rapid test for COVID-19 returned

patient also had acute kidney injury (AKI)

positive,

and mild transaminitis. He had a metabolic

negative.

AKI = acute kidney injury
COVID-19 = coronavirus
disease-2019

ED = emergency department
FS = fractional shortening
hsTnT = high-sensitivity
troponin T

IVIG = intravenous
immunoglobulin

and

respiratory

viral

PCR

panel

was

acidosis with an initial lactate of 6.4 mmol/l.

He was admitted to the PICU on room air.

Nasopharyngeal polymerase chain reaction

Contemporaneous TTE showed low-normal LVEF of

(PCR) testing for COVID-19 returned positive,

56%, FS of 29%, mild mitral regurgitation, and hol-

and a respiratory viral panel was negative. An

odiastolic reversal of ﬂow in the descending aorta.

initial chest x-ray ﬁlm showed a left basal

Epinephrine infusion was added at this time because

opacity, with no cardiomegaly.

of continued hypotension. He was treated with a 5-

He was admitted to the PICU, where

day course of hydroxychloroquine, as well as intra-

fraction

bedside cardiac ultrasound showed moder-

venous tocilizumab. By 36 h of admission, all

PCR = polymerase chain

ately decreased function (fractional short-

inotropic support had been weaned off and his AKI

reaction

ening [FS] 18%) with no pericardial effusion.

had resolved. He was discharged on PICU day 3. His

PICU = pediatric intensive care

Owing to increasing lactate levels, he was

inﬂammatory markers trended down at discharge and

unit

intubated, placed on a ventilator, sedated,

his echocardiography showed an LVEF of 57% and an

TTE = transthoracic

and chemically paralyzed. Epinephrine and

FS of 35%.

LVEF = left ventricular ejection

echocardiogram

milrinone infusions were initiated. He was

VIS = vasoactive ionotropic

treated with tocilizumab, an interleukin-6

score

inhibitor, and intravenous immunoglobulin
(IVIG) on PICU day 1 and transthoracic echocardiography (TTE) showed improvement in left ventricular
function with a FS of 32% and left ventricular ejection
fraction (LVEF) of 49%. Remdesivir, an antiviral that
inhibits

COVID-19

replication,

and

intravenous

methylprednisolone were started on PICU day 2.
His course was complicated by brief episodes of
atrial tachycardia. By PICU day 4, he was off inotropic
infusions and extubated to non-invasive ventilation,
and by PICU day 5, he was weaned to room air with
downtrending inﬂammatory markers and troponin
levels. A repeat echocardiogram on PICU day 5
showed improved function (FS 45% and LVEF 65%)
and he was discharged on PICU day 11 after
completing his remdesivir course.

PATIENT #2

PATIENT #3
A 13-year-old female patient with a known small
midmuscular ventricular septal defect presented to
the ED with 9 days of intermittent fever, headache,
and cough and 5 days of abdominal pain and diarrhea.
On initial presentation, she was febrile (39.4  C),
tachycardic

(119

beats/min),

normotensive

(117/

68 mmHg), and mildly tachypneic (18 breaths/min),
with oxygen saturation of 100% on room air. On examination, she was awake and alert, and had good air
entry with diminished breath sounds at the bases,
normal heart sounds, mild epigastric abdominal
tenderness, and normal peripheral perfusion with
brisk capillary reﬁll. For tachycardia, she received a
10-cm 3/kg ﬂuid bolus with minimal improvement in
heart rate. Initial laboratory results showed an
elevated white blood cell count with a left shift and
bandemia. She also had a signiﬁcant elevation in inﬂammatory markers that have been associated with

A 6-year-old male patient with history of mild

COVID-19. The patient had normal renal function. Her

persistent asthma presented to the ED with 6 days of

hsTnT was 43 ng/l (<6 to 14 ng/l). Nasopharyngeal

fever, pharyngitis, myalgia, and abdominal pain and

PCR testing for COVID-19 returned positive, and a

1 day of diarrhea and shortness of breath. On initial

respiratory viral panel was negative.

presentation, he was afebrile, tachycardic (130 beats/

She was admitted to the pediatric ward, where she

min), hypotensive (71/34 mm Hg), and tachypneic (40

received additional ﬂuid boluses for worsening

breaths/min), with oxygen saturation of 97% on room

tachycardia (134 beats/min) and hypotension (85/

air. On examination, he had good air entry bilaterally,

45 mm Hg). Given the abnormal hsTnT and persistent

with an III/VI systolic murmur appreciated at the left

tachycardia, a TTE was performed, which showed

upper sternal border. A norepinephrine infusion was

moderately decreased left ventricular systolic func-

started for ﬂuid refractory hypotension.

tion with an LVEF of 40%, FS of 21% with mild mitral

Initial laboratory results showed a leukocytosis

regurgitation, holodiastolic ﬂow reversal in the

with neutrophil predominance and bandemia as well

descending aorta, and a small pericardial effusion.

as signiﬁcant elevation in inﬂammatory markers that

She was transferred to the PICU, started on a milri-

have been associated with COVID-19. He had a normal

none

infusion,

and

continued

treatment

with
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T A B L E 1 Comparison of Presenting Symptoms, Echocardiographic Findings, and Labs Among 3 COVID-19 Patients

Patient #1

Patient #2

Patient #3

Presenting symptoms

Fever, headache, abdominal pain, diarrhea,
dyspnea

Fever, pharyngitis, myalgia, abdominal
pain, diarrhea, dyspnea

Fever, headache, cough abdominal pain
and diarrhea

Cardiac rhythm

Sinus tachycardia
Nonspeciﬁc ST- and T-wave abnormalities
Atrial tachycardia on PICU day 3

Sinus tachycardia
Nonspeciﬁc T-wave abnormalities

Sinus tachycardia
Right axis deviation
Nonspeciﬁc T-wave abnormalities

Initial LVEF/FS, %

—/18

56/29

40/21

Discharge LVEF/FS, %

65/45

57/35

54/28
Holodiastolic ﬂow reversal

Initial descending aortic Doppler

N/A

Holodiastolic ﬂow reversal

Peak VIS

26

18

5

Peak lactate, mmol/l

11

1.5

2.8

Peak hsTnT, ng/l
Peak ferritin, ng/ml

475

116

43

1,426

1,985

375.8

Peak WBC count, K/ml

28.1

15.8

10.3

Peak D-dimer, ng/ml

1,973

2,829

508

313

300

347

Peak ﬁbrinogen, mg/dl

1,145

582

771

Peak triglycerides, mg/dl

987

813

191

425.3

361.1

216.3

4.4

35

2.45

Tocilizumab
Remdesivir
IVIG
Steroids

Tocilizumab
Hydroxychloroquine

Hydroxychloroquine

Enoxaparin (therapeutic)

Enoxaparin (therapeutic)

None

11*

4

4

Peak LDH, U/l

Peak C-reactive protein, mg/l
Peak procalcitonin, ng/ml
COVID-19 therapies received

Anticoagulation
Length of PICU stay, days

*Patient was stable for discharge on hospital day 7 but remained in hospital to complete the 10-day course of remdesivir.
COVID-19 ¼ coronavirus disease-2019; FS ¼ fractional shortening; hsTnT ¼ high-sensitivity troponin T; IVIG ¼ intravenous immunoglobulin; LDH ¼ lactic dehydrogenase; LVEF ¼ left ventricular ejection
fraction; N/A ¼ not assessed; PICU ¼ pediatric intensive care unit; VIS ¼ vasoactive ionotropic score; WBC ¼ white blood cell.

hydroxychloroquine. By PICU day 2, her inﬂamma-

of distributive shock and cytokine release syndrome,

tory markers and hsTnT had improved. A repeat

with elevated troponin levels and inﬂammatory
Two

demonstrated

holodiastolic

ﬂow

echocardiogram on PICU day 3 showed improved

markers.

LVEF to 54% and FS to 28%, and milrinone was dis-

reversal in the descending aorta, suggestive of severe

continued. She was discharged on PICU day 4.

vasodilation, which appears to support this hypothesis. None of our patients had other symptoms of

DISCUSSION

classic Kawasaki disease or evidence of coronary
involvement.

Studies suggest a milder clinical course in children,

The other postulated theory of cardiac injury is

with very few requiring intensive care (1). There are

direct viral infection causing myocarditis. A report on

currently limited data regarding cardiovascular and

endomyocardial biopsy in COVID-19 has shown both

myocardial involvement in pediatric patients with

viral particles and inﬂammatory inﬁltrate in the

COVID-19, although anecdotal reports of a shock-like

myocardium (5).

presentation with features of Kawasaki disease with

Currently, there are no established treatment rec-

myocarditis exist (2). We present 3 pediatric patients

ommendations for cardiac injury and inﬂammation

admitted to intensive care with shock and evidence of

related to COVID-19 infection. Steroids and IVIG have

cardiac injury (Table 1).

been described as treatments in adult COVID-19

The

mechanism

for

COVID-19–related

cardiac

myocarditis with unclear beneﬁt (6). Both IVIG and

injury and shock is unclear. One proposed theory is

steroids were utilized to treat patient 1, our patient

cytokine-mediated

(3).

with the most severe clinical presentation. Tocilizu-

Cytokine release appears to be a major causative eti-

mab, an interleukin-6 inhibitor, was used in Patients

myocardial

inﬂammation

ology in the multiorgan dysfunction seen in COVID-19

#1 and #2 per an institutional guideline (7). Antiviral

patients and can adversely impact myocardial func-

therapies were also used.

tion along with the function of other vital organ sys-

These cases demonstrate that COVID-19 infection

tems (4). All 3 of our patients presented with features

can cause severe illness in previously healthy
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children. Shock and cardiac dysfunction can be a

proportion have required intensive care. We antici-

signiﬁcant component of illness independent of lung

pate addressing this growing patient population in

disease. Further studies are ultimately needed to

more detail in future papers, and hope that this case

determine the optimal treatment for these patients.

series will raise awareness of a particular subset of

Long-term follow-up is important to understand the

cardiac

pathophysiology and long-term prognosis of children

COVID-19.

dysfunction

and

shock

associated

with

with cardiac injury resulting from COVID-19. As this
case series goes to press, our hospital has admitted

ADDRESS FOR CORRESPONDENCE: Dr. Christine A.

more than 100 children with COVID-19–related ill-

Capone, Pediatric Critical Care Medicine, Steven and

nesses, including more than 30 children with various

Alexandra Cohen Children’s Medical Center of New

cardiac manifestations of COVID-19. Of these chil-

York, 269-01 76th Avenue, New Hyde Park, New

dren admitted with cardiac manifestations, a large

York 11040. E-mail: ccapone@northwell.edu.
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